Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING-COM: Stroke Prevention in Sickle Cell Anaemia
NCT05434000Unknown
- Sponsor
- Barau Dikko Teaching Hospital
- Start
- Jan 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of hydroxyurea in sickle cell anemia (SCA) (2 arms), sponsored by Barau Dikko Teaching Hospital. Primary endpoints: Reach (Participation Rate) at 1 year and Effectiveness (Stroke Aversion) at 1 year. Status: unknown.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT05434000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05434000.